• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Development and Optimization of C-Labeled Radiotracers: A Review of the Modern Quality Control Design Process.碳标记放射性示踪剂的研发与优化:现代质量控制设计流程综述
ACS Pharmacol Transl Sci. 2023 Oct 11;6(11):1616-1631. doi: 10.1021/acsptsci.3c00200. eCollection 2023 Nov 10.
2
Two decades of [C]PiB synthesis, 2003-2023: a review.2003年至2023年[C]PiB合成的二十年回顾
Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):48-62. doi: 10.62347/ADSK6584. eCollection 2024.
3
New protein deposition tracers in the pipeline.正在研发的新型蛋白质沉积示踪剂。
EJNMMI Radiopharm Chem. 2017;1(1):11. doi: 10.1186/s41181-016-0015-3. Epub 2016 Jun 2.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.氟-18 标记的 PET 放射性示踪剂用于成像色氨酸摄取和代谢:系统评价。
Mol Imaging Biol. 2020 Aug;22(4):805-819. doi: 10.1007/s11307-019-01430-6.
6
Molecular imaging of dementia.痴呆的分子影像学。
Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x.
7
Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers.提高放射性摩尔量的速度至关重要:快速 HPLC 缩短了 C-11 PET 示踪剂的质量控制时间。
Nucl Med Biol. 2018 Feb;57:28-33. doi: 10.1016/j.nucmedbio.2017.11.006. Epub 2017 Nov 21.
8
Toward miniaturized analysis of chemical identity and purity of radiopharmaceuticals via microchip electrophoresis.通过微芯片电泳实现放射性药物化学特性和纯度的小型化分析。
Anal Bioanal Chem. 2018 Mar;410(9):2423-2436. doi: 10.1007/s00216-018-0924-y. Epub 2018 Feb 22.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain.双示踪剂 tau PET 成像显示 C-THK5351 和 C-PBB3 在阿尔茨海默病大脑中针对不同的分子靶点。
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1605-1617. doi: 10.1007/s00259-018-4012-5. Epub 2018 May 12.

引用本文的文献

1
Synthesis and in vivo biological characterization of six carbon-11 sigma-1 receptor radiotracers in rodent and nonhuman primate.六种碳-11 σ-1受体放射性示踪剂在啮齿动物和非人灵长类动物中的合成及体内生物学特性研究
Bioorg Med Chem. 2025 Aug 15;126:118218. doi: 10.1016/j.bmc.2025.118218. Epub 2025 Apr 28.
2
Two decades of [C]PiB synthesis, 2003-2023: a review.2003年至2023年[C]PiB合成的二十年回顾
Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):48-62. doi: 10.62347/ADSK6584. eCollection 2024.

本文引用的文献

1
Computational Chemistry for the Identification of Lead Compounds for Radiotracer Development.用于放射性示踪剂开发的先导化合物鉴定的计算化学
Pharmaceuticals (Basel). 2023 Feb 18;16(2):317. doi: 10.3390/ph16020317.
2
In Vivo Imaging and Kinetic Modeling of Novel Glycogen Synthase Kinase-3 Radiotracers [C]OCM-44 and [F]OCM-50 in Non-Human Primates.新型糖原合酶激酶-3放射性示踪剂[C]OCM-44和[F]OCM-50在非人灵长类动物中的体内成像及动力学建模
Pharmaceuticals (Basel). 2023 Jan 28;16(2):194. doi: 10.3390/ph16020194.
3
Binding Parameters of [C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents.微管成像PET放射性药物[C]MPC - 6827在啮齿动物中的结合参数
Pharmaceuticals (Basel). 2023 Mar 27;16(4):495. doi: 10.3390/ph16040495.
4
Understanding the importance of quality control and quality assurance in preclinical PET/CT imaging.了解临床前PET/CT成像中质量控制和质量保证的重要性。
EJNMMI Phys. 2022 Oct 31;9(1):77. doi: 10.1186/s40658-022-00503-w.
5
Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain α2C adrenergic receptors.新型 C-11 标记苯并-1,4-二恶烷 PET 放射性示踪剂用于脑 α2C 肾上腺素能受体的临床前评估。
Eur J Med Chem. 2022 Dec 5;243:114764. doi: 10.1016/j.ejmech.2022.114764. Epub 2022 Sep 17.
6
First-in-human use of C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor.首次在人体中使用C-CPPC结合正电子发射断层扫描成像巨噬细胞集落刺激因子1受体。
EJNMMI Res. 2022 Sep 30;12(1):64. doi: 10.1186/s13550-022-00929-4.
7
Comparison of brain nicotine uptake from electronic cigarettes and combustible cigarettes.比较电子烟和可燃香烟对大脑尼古丁的摄取。
Neuropsychopharmacology. 2022 Oct;47(11):1939-1944. doi: 10.1038/s41386-022-01410-5. Epub 2022 Aug 12.
8
Radiosynthesis and Evaluation of a C-11 Radiotracer for Transient Receptor Potential Canonical 5 in the Brain.放射性合成与脑内瞬时受体电位经典型 5 放射性示踪剂的评价。
Mol Imaging Biol. 2023 Apr;25(2):334-342. doi: 10.1007/s11307-022-01760-y. Epub 2022 Aug 11.
9
Screening of σ Receptor Ligands and Evaluation of C-Labeled 6,7-Dimethoxy-2-[4-(4-methoxyphenyl)butan-2-yl]-1,2,3,4-tetrahydroisoquinoline for Potential Use as a σ Receptor Brain PET Tracer.σ受体配体的筛选以及用于潜在σ受体脑PET示踪剂的碳-11标记的6,7-二甲氧基-2-[4-(4-甲氧基苯基)丁-2-基]-1,2,3,4-四氢异喹啉的评估
J Med Chem. 2022 Apr 28;65(8):6261-6272. doi: 10.1021/acs.jmedchem.2c00191. Epub 2022 Apr 11.
10
Method to Development of PET Radiopharmaceutical for Cancer Imaging.用于癌症成像的正电子发射断层显像(PET)放射性药物的开发方法。
Methods Mol Biol. 2022;2413:13-22. doi: 10.1007/978-1-0716-1896-7_3.

碳标记放射性示踪剂的研发与优化:现代质量控制设计流程综述

Development and Optimization of C-Labeled Radiotracers: A Review of the Modern Quality Control Design Process.

作者信息

Myburgh Paul Josef, Sai Kiran Kumar Solingapuram

机构信息

Translational Imaging Program, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina 27157, United States.

Department of Radiology, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina 27157, United States.

出版信息

ACS Pharmacol Transl Sci. 2023 Oct 11;6(11):1616-1631. doi: 10.1021/acsptsci.3c00200. eCollection 2023 Nov 10.

DOI:10.1021/acsptsci.3c00200
PMID:37974626
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10644505/
Abstract
  • Several C-tracers have demonstrated high potential in early diagnostic PET imaging applications of neurodegenerative diseases including Alzheimer's and Parkinson's disease. These radiotracers often track critical biomarkers in disease pathogenesis such as tau fibrils ([C]PBB3) or β-amyloid plaques ([C]PiB) associated with such diseases. - The short review aims to serve as a guideline in the future development of radiotracers for students, postdocs and/or new radiochemists who will be synthesizing clinical grade or novel research C-tracers, including knowledge of regulatory requirements. We aim to bridge the gap between novel and established C-tracer quality control (QC) processes through exploring the design process and regulatory requirements for C-pharmaceuticals. - A literature survey was undertaken to identify articles with a detailed description of the QC methodology and characterization for each of the sections of the review. - First a general summary of C-tracer production was presented; this was used to establish possible places for contamination or assurances for a sterile final product. The key mandated QC analyses for clinical use were then discussed. Further, we assessed the QC methods used for established C-tracers and then reviewed the routine QC tests for preclinical translational and validation studies. Therefore, both mandated QC methods for clinical and preclinical animal studies were reviewed. Last, some examples of optimization and automation were reviewed, and implications of the QC practices associated with such procedures were considered. - All of the common QC parameters associated with C-tracers under clinical and preclinical settings (along with a few exceptions) were discussed in detail. While it is important to establish standard, peer-reviewed QC testing protocols for a novel C-tracer entering the clinical umbrella, equal importance is needed on preclinical applications to address credibility and repeatability for the study.
摘要
  • 几种碳(C)示踪剂在神经退行性疾病(包括阿尔茨海默病和帕金森病)的早期诊断正电子发射断层显像(PET)应用中已显示出巨大潜力。这些放射性示踪剂通常追踪疾病发病机制中的关键生物标志物,如与这些疾病相关的tau原纤维([C]PBB3)或β淀粉样斑块([C]PiB)。

  • 这篇简短综述旨在为未来合成临床级或新型研究用碳示踪剂的学生、博士后和/或新的放射化学家提供放射性示踪剂开发指南,包括监管要求方面的知识。我们旨在通过探索碳药物的设计过程和监管要求,弥合新型和既定碳示踪剂质量控制(QC)流程之间的差距。

  • 进行了文献调查,以确定对综述各部分的质量控制方法和特性有详细描述的文章。

  • 首先介绍了碳示踪剂生产的总体概况;这用于确定可能的污染点或确保最终产品无菌。然后讨论了临床使用所需的关键质量控制分析。此外,我们评估了既定碳示踪剂所使用的质量控制方法,接着回顾了临床前转化和验证研究的常规质量控制测试。因此,对临床和临床前动物研究所需的质量控制方法都进行了综述。最后,回顾了一些优化和自动化的例子,并考虑了与此类程序相关的质量控制实践的影响。

  • 详细讨论了临床和临床前环境下与碳示踪剂相关的所有常见质量控制参数(有一些例外情况)。虽然为进入临床阶段的新型碳示踪剂建立标准的、经过同行评审的质量控制测试方案很重要,但临床前应用对于确保研究的可信度和可重复性同样重要。